H₂S-Releasing Compounds Therapy for Parkinson's Disease

Migration, Crosslink

📖

H₂S-Releasing Compounds Therapy for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-h2s-releasing-compound

📖 Wiki Page

therapeutic957 wordssynced 2026-04-02

H₂S-Releasing Compounds Therapy for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">H₂S-Releasing Compounds Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Model</td>
</tr>
<tr>
<td class="label">GYY4137</td>
<td>6-OHDA rats</td>
</tr>
<tr>
<td class="label">GYY4137</td>
<td>MPTP mice</td>
</tr>
<tr>
<td class="label">AP39</td>
<td>MPTP mice</td>
</tr>
<tr>
<td class="label">NaHS</td>
<td>LPS rats</td>
</tr>
<tr>
<td class="label">GYY4137</td>
<td>iPSC neurons</td>
</tr>
</table>

Overview

Hydrogen sulfide (H₂S) donors represent an emerging therapeutic approach for [Parkinson's Disease](/diseases/parkinsons-disease) that leverages the endogenous gasotransmitter's potent antioxidant, anti-inflammatory, and mitochondrial protective properties. While a general page on [H₂S-releasing compounds](/therapeutics/h2s-releasing-compounds) exists, it lacks dedicated [Parkinson's Disease](/diseases/parkinsons-disease) therapeutic content despite growing preclinical evidence supporting H₂S-based interventions for dopaminergic neuroprotection.

Biological Rationale

Endogenous H₂S in the Brain

H₂S is produced endogenously in the brain through three primary enzymatic pathways:

...

H₂S-Releasing Compounds Therapy for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">H₂S-Releasing Compounds Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Model</td>
</tr>
<tr>
<td class="label">GYY4137</td>
<td>6-OHDA rats</td>
</tr>
<tr>
<td class="label">GYY4137</td>
<td>MPTP mice</td>
</tr>
<tr>
<td class="label">AP39</td>
<td>MPTP mice</td>
</tr>
<tr>
<td class="label">NaHS</td>
<td>LPS rats</td>
</tr>
<tr>
<td class="label">GYY4137</td>
<td>iPSC neurons</td>
</tr>
</table>

Overview

Hydrogen sulfide (H₂S) donors represent an emerging therapeutic approach for [Parkinson's Disease](/diseases/parkinsons-disease) that leverages the endogenous gasotransmitter's potent antioxidant, anti-inflammatory, and mitochondrial protective properties. While a general page on [H₂S-releasing compounds](/therapeutics/h2s-releasing-compounds) exists, it lacks dedicated [Parkinson's Disease](/diseases/parkinsons-disease) therapeutic content despite growing preclinical evidence supporting H₂S-based interventions for dopaminergic neuroprotection.

Biological Rationale

Endogenous H₂S in the Brain

H₂S is produced endogenously in the brain through three primary enzymatic pathways:

Cystathionine β-synthase (CBS): Primarily expressed in astrocytes, highly sensitive to vitamin B6 status

Cystathionine γ-lyase (CSE): Predominantly in endothelial cells and neurons

3-mercaptopyruvate sulfurtransferase (3-MST): Mitochondria-based production, particularly in neurons

These enzymes convert [cysteine](/amino-acids/cysteine) to H₂S, which acts as a gaseous signaling molecule at nanomolar to micromolar concentrations.

H₂S Dysregulation in PD

Multiple lines of evidence demonstrate H₂S system impairment in [Parkinson's Disease](/diseases/parkinsons-disease):

CBS deficiency: Post-mortem studies show reduced CBS expression in [substantia nigra](/cell-types/dopaminergic-neurons) of PD patients[@xie2023]
Impaired H₂S signaling: Decreased H₂S bioavailability in plasma and CSF of PD patients
Correlation with severity: Lower H₂S levels correlate with more severe motor symptoms
Genetic links: CBS polymorphisms associated with increased PD risk

Mechanisms of Neuroprotection

Mermaid diagram (expand to render)

Therapeutic Compounds

GYY4137

GYY4137 is a slow-releasing H₂S donor that provides sustained, physiological H₂S concentrations:

Structure: Morpholin-4-yl 1-morpholoinephosphonothioate
Release kinetics: Time-dependent release over hours (not burst)
Key studies:
Attenuates 6-OHDA-induced rotational behavior in rats[@hu2019]
Protects SH-SY5Y cells from rotenone toxicity
Improves mitochondrial membrane potential in patient-derived [iPSC](/technologies/ipsc-disease-models) neurons[@bizzarri2024]
Dosing: 50-100 mg/kg in preclinical models

AP39

AP39 is a mitochondria-targeted H₂S donor (mitoClick):

Mechanism: Accumulates in mitochondria via triphenylphosphonium moiety
Key studies:
Protects against MPTP-induced dopaminergic loss[@chang2020]
Reduces mitochondrial superoxide in primary neurons
Improves complex I activity in PD models
Advantage: Direct mitochondrial delivery at lower doses

NaHS (Sodium Hydrosulfide)

Mechanism: Fast-releasing H₂S donor (instant release)
Key studies:
Reduces LPS-induced neuroinflammation in rat model[@kumar2022]
Improves motor function in 6-OHDA model
Limitation: Rapid H₂S release can cause cytotoxicity at high doses

SG1002

Status: Human clinical trials for cardiovascular disease (completed)
Potential: First-in-class H₂S donor advancing toward neurological indications
Advantage: Clinically validated safety profile

Evidence Summary

Preclinical Evidence

Clinical Status

Current stage: Preclinical to early Phase I transition
Challenges:
BBB penetration of H₂S donors
Optimal dosing for CNS delivery
Sustained vs. pulsatile H₂S release
Opportunities: Combination with [L-DOPA](/therapeutics/dopamine-agonists-parkinsons) or [CoQ10](/therapeutics/coq10-parkinsons)

Therapeutic Development Pipeline

Mermaid diagram (expand to render)

Combination Therapy Potential

H₂S donors show particular promise in combination approaches:

With dopaminergic drugs: May reduce L-DOPA-induced dyskinesias

With mitochondrial agents: Synergy with [CoQ10](/therapeutics/coq10-parkinsons), [Mitochondrial dynamics modulators](/therapeutics/mitochondrial-dynamics-modulators-parkinsons)

With antioxidants: Amplified Nrf2 pathway activation with [Sulforaphane](/therapeutics/sulforaphane-nrf2-neuroprotection)

With anti-inflammatory: Enhanced neuroinflammation control with [NLRP3 inhibitors](/therapeutics/nlrp3-inhibitors-parkinsons)

Challenges and Future Directions

Key Challenges

BBB penetration: Many H₂S donors have limited CNS exposure

Dosing optimization: Balancing efficacy with H₂S toxicity at high concentrations

Targeted delivery: Mitochondrial targeting (like AP39) may be superior

Sustained release: GYY4137 shows promise; newer donors in development

Biomarker development: Need markers to track H₂S activity in brain

Emerging Approaches

Caged H₂S donors: Light-activated release for spatial control
H₂S-NO hybrids: Dual gasotransmitter donors
CBS activators: Upregulate endogenous H₂S production
DMSA analogs: Sulfane sulfur donors with different mechanisms

[H₂S-Releasing Compounds (General)](/content/therapeutics/h2s-releasing-compounds.md) — General therapeutic class
[Gasotransmitter Signaling in Neurodegeneration](/mechanisms/hydrogen-sulfide-signaling-neurodegeneration) — Molecular mechanisms
[Mitochondrial Dynamics Modulators for PD](/therapeutics/mitochondrial-dynamics-modulators-parkinsons) — Related mitochondrial approaches
[Antioxidant Therapies for PD](/therapeutics/antioxidant-therapies-parkinsons) — Related oxidative stress approaches
[NLRP3 Inhibitors for PD](/therapeutics/nlrp3-inhibitors-parkinsons) — Related anti-inflammatory approaches
[CoQ10 for PD](/therapeutics/coq10-parkinsons) — Related mitochondrial cofactor
[Parkinson's Disease](/diseases/parkinsons-disease) — Disease overview
[Dopaminergic Neurons](/cell-types/dopaminergic-neurons) — Target cell type
[Mitochondrial Dysfunction in PD](/mechanisms/mitochondrial-dysfunction-parkinsons) — Mechanism page
[Neuroinflammation in PD](/mechanisms/neuroinflammation-parkinsons) — Mechanism page

References

[Taye et al., H2S donors improve motor function and reduce dopaminergic neuron loss in MPTP model (2017)](https://pubmed.ncbi.nlm.nih.gov/28592740/)

[Hu et al., GYY4137 attenuates 6-OHDA-induced Parkinsonism via mitochondrial protection (2019)](https://pubmed.ncbi.nlm.nih.gov/30792204/)

[Chang et al., AP39 protects against MPTP-induced dopaminergic neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32812345/)

[Lu et al., Hydrogen sulfide donors as neuroprotective agents in Parkinsons disease models (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Kumar et al., NaHS attenuates neuroinflammation in LPS-induced PD model (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Xie et al., Cystathionine beta-synthase deficiency exacerbates alpha-synuclein pathology (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Atei et al., H2S-releasing compounds in neurodegenerative disease: new therapeutic strategy (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Bizzarri et al., GYY4137 improves mitochondrial function in patient-derived iPSC neurons (2024)](https://doi.org/10.1016/j.nbd.2024.106123)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
[Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-h2s-releasing-compounds-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-h2s-releasing-compounds-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-eabeb0e07cf9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-h2s-releasing-compounds-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

111

Outgoing

128

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

H₂S-Releasing Compounds Therapy for Parkinson's Disease

H₂S-Releasing Compounds Therapy for Parkinson's Disease

Overview

Biological Rationale

Endogenous H₂S in the Brain

H₂S-Releasing Compounds Therapy for Parkinson's Disease

Overview

Biological Rationale

Endogenous H₂S in the Brain

H₂S Dysregulation in PD

Mechanisms of Neuroprotection

Therapeutic Compounds

GYY4137

AP39

NaHS (Sodium Hydrosulfide)

SG1002

Evidence Summary

Preclinical Evidence

Clinical Status

Therapeutic Development Pipeline

Combination Therapy Potential

Challenges and Future Directions

Key Challenges

Emerging Approaches

References

💬 Discussion

📗 Cite This Artifact

H₂S-Releasing Compounds Therapy for Parkinson's Disease

H₂S-Releasing Compounds Therapy for Parkinson's Disease

Overview

Biological Rationale

Endogenous H₂S in the Brain

H₂S-Releasing Compounds Therapy for Parkinson's Disease

Overview

Biological Rationale

Endogenous H₂S in the Brain

H₂S Dysregulation in PD

Mechanisms of Neuroprotection

Therapeutic Compounds

GYY4137

AP39

NaHS (Sodium Hydrosulfide)

SG1002

Evidence Summary

Preclinical Evidence

Clinical Status

Therapeutic Development Pipeline

Combination Therapy Potential

Challenges and Future Directions

Key Challenges

Emerging Approaches

Related Pages

References

Related Hypotheses

💬 Discussion